263 related articles for article (PubMed ID: 24057925)
41. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
[TBL] [Abstract][Full Text] [Related]
42. Rare presentation of secondary cutaneous involvement by splenic marginal zone lymphoma: report of a case and review of the literature.
Cohen JM; Nazarian RM; Ferry JA; Takvorian RW; Carter JB
Am J Dermatopathol; 2015 Jan; 37(1):e1-4. PubMed ID: 25238446
[TBL] [Abstract][Full Text] [Related]
43. Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes.
Iannitto E; Minardi V; Calvaruso G; Ammatuna E; Florena AM; Mulè A; Tripodo C; Quintini G; Abbadessa V
Eur J Haematol; 2005 Aug; 75(2):130-5. PubMed ID: 16000129
[TBL] [Abstract][Full Text] [Related]
44. Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab Eras in the United States.
Shah BK; Bista A; Shafii B
Anticancer Res; 2014 Sep; 34(9):5117-20. PubMed ID: 25202101
[TBL] [Abstract][Full Text] [Related]
45. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
46. Treatment of older patients with mantle-cell lymphoma.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
[TBL] [Abstract][Full Text] [Related]
47. Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study.
Muntañola A; Villalobos MT; González-Villambrosia S; Rodríguez-Salazar MJ; Jiménez-Ubieto A; Bastidas-Mora G; Córdoba R; Infante M; Vidal MJ; Díaz FJ; Baile M; Bastos-Oreiro M; Panizo C; Sancho JM; Navarro B; García T; Escoda L; Abrisqueta P; Terol MJ; de Campo R; Mozas P; López-Guillermo A; Salar A; Montalbán C;
Br J Haematol; 2023 Aug; 202(4):776-784. PubMed ID: 37386877
[TBL] [Abstract][Full Text] [Related]
48. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
[TBL] [Abstract][Full Text] [Related]
49. Diagnostic and therapeutic splenectomy for splenic lymphomas: analysis of the National Cancer Data Base.
Fallah J; Olszewski AJ
Hematology; 2019 Dec; 24(1):378-386. PubMed ID: 30885066
[TBL] [Abstract][Full Text] [Related]
50. Surgical management of splenic marginal zone lymphoma.
Kennedy ND; Lê GN; Kelly ME; Harding T; Fadalla K; Winter DC
Ir J Med Sci; 2018 May; 187(2):343-347. PubMed ID: 29043543
[TBL] [Abstract][Full Text] [Related]
51. Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
Zinzani PL; Pellegrini C; Broccoli A; Casadei B; Argnani L; Pileri S
Am J Hematol; 2013 Nov; 88(11):E273-6. PubMed ID: 23843267
[TBL] [Abstract][Full Text] [Related]
52. Intrapericardial and intrapleural administration of rituximab to a patient with marginal zone lymphoma.
Boguradzki P; Drozd-Sokolowska JE; Wieczorek J; Kowalik R; Starczewska M; Krol M; Kobylecka M; Opolski G; Wiktor-Jedrzejczak W
Acta Haematol; 2013; 130(3):169-71. PubMed ID: 23735747
[TBL] [Abstract][Full Text] [Related]
53. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria.
Matutes E; Oscier D; Montalban C; Berger F; Callet-Bauchu E; Dogan A; Felman P; Franco V; Iannitto E; Mollejo M; Papadaki T; Remstein ED; Salar A; Solé F; Stamatopoulos K; Thieblemont C; Traverse-Glehen A; Wotherspoon A; Coiffier B; Piris MA
Leukemia; 2008 Mar; 22(3):487-95. PubMed ID: 18094718
[TBL] [Abstract][Full Text] [Related]
54. Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.
Zaja F; Mian M; Volpetti S; Visco C; Sissa C; Nichele I; Castelli M; Ambrosetti A; Puglisi S; Fanin R; Cortelazzo S; Pizzolo G; Trentin L; Rodeghiero F; Paolini R; Vivaldi P; Sancetta R; Isola M; Semenzato G
Am J Hematol; 2013 Nov; 88(11):955-60. PubMed ID: 23861234
[TBL] [Abstract][Full Text] [Related]
55. Splenic marginal zone lymphoma: from genetics to management.
Arcaini L; Rossi D; Paulli M
Blood; 2016 Apr; 127(17):2072-81. PubMed ID: 26989207
[TBL] [Abstract][Full Text] [Related]
56. Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?
Kalpadakis C; Pangalis GA; Angelopoulou MK; Sachanas S; Vassilakopoulos TP
Best Pract Res Clin Haematol; 2018 Mar; 31(1):65-72. PubMed ID: 29452668
[TBL] [Abstract][Full Text] [Related]
57. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
[TBL] [Abstract][Full Text] [Related]
58. Idelalisib and Rituximab in 17p Deletion-Positive Splenic Marginal Zone Lymphoma.
Philip AZ
J Natl Compr Canc Netw; 2018 Mar; 16(3):230-233. PubMed ID: 29523661
[TBL] [Abstract][Full Text] [Related]
59. Long-term outcome and patterns of failure in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy.
Hashimoto N; Sasaki R; Nishimura H; Yoshida K; Miyawaki D; Nakayama M; Uehara K; Okamoto Y; Ejima Y; Azumi A; Matsui T; Sugimura K
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1509-14. PubMed ID: 21664061
[TBL] [Abstract][Full Text] [Related]
60. Clinical manifestations of primary pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in Japanese population.
Ogusa E; Tomita N; Ishii Y; Takasaki H; Hattori Y; Matsumoto C; Ishigatsubo Y
Hematol Oncol; 2013 Mar; 31(1):18-21. PubMed ID: 22278757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]